创模生物科技(北京)有限公司

CN / En

NEWS

The InnoModels Intracorporeal Tumor Platform: Features and Sub-Platform Introduction

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-16 15:46
  • Views:

(Summary description)InnoModels' in vivo tumor experimental platform is a major breakthrough in the field of biotechnology and medical research in recent years. With its highly accurate simulation, accelerated drug development, and support for multidisciplinary research, the platform provides unprecedented experimental conditions and convenience for researchers. In this article, we will introduce in detail the features of the InnoModels BioIntracellular Tumor Experiment Platform and its sub-platforms.

The InnoModels Intracorporeal Tumor Platform: Features and Sub-Platform Introduction

(Summary description)InnoModels' in vivo tumor experimental platform is a major breakthrough in the field of biotechnology and medical research in recent years. With its highly accurate simulation, accelerated drug development, and support for multidisciplinary research, the platform provides unprecedented experimental conditions and convenience for researchers. In this article, we will introduce in detail the features of the InnoModels BioIntracellular Tumor Experiment Platform and its sub-platforms.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-16 15:46
  • Views:
Information

InnoModels' in vivo tumor experimental platform is a major breakthrough in the field of biotechnology and medical research in recent years. With its highly accurate simulation, accelerated drug development, and support for multidisciplinary research, the platform provides unprecedented experimental conditions and convenience for researchers. In this article, we will introduce in detail the features of the InnoModels BioIntracellular Tumor Experiment Platform and its sub-platforms.
First of all, let's take a look at the main features of InnoModels' in vivo tumor platform. The platform provides researchers with reliable experimental data and results by highly simulating the complexity of tumors in the human body. Whether it is breast cancer, lung cancer or gastrointestinal tumors, the platform provides researchers with a wealth of options to better meet different research needs. In addition, by simulating the in vivo environment, including the immune system, blood supply and other factors, the platform can provide more realistic experimental conditions, which helps to more accurately assess the performance and potential efficacy of drugs in vivo.
In terms of accelerating drug development, the InnoModels Biotechnology in vivo tumor platform offers significant advantages. Researchers can utilize the platform to more rapidly assess the efficacy and safety of drugs, thereby significantly shortening the drug development cycle. This not only helps to accelerate the time to market for new drugs, but also provides patients with more timely and effective treatment options.

 


Supporting multidisciplinary research is also a major feature of the InnoModels Biotechnology in vivo tumor experimental platform. The platform is not only suitable for basic science research, but also widely used in clinical research and translational medicine. It provides strong support for multidisciplinary collaboration, enabling researchers to more comprehensively understand the occurrence, development and treatment mechanisms of tumors.
Next, let's take a look at the sub-platforms of InnoModels' in vivo tumor experimental platform. Among them, the MHC knockout mouse model is an important sub-platform. This model provides a specific evaluation environment for Car-T cell therapy by knocking out the MHC gene in mice. This model is designed to mimic the actual response of Car-T cells in the human body, thus providing researchers with experimental data closer to the clinic. In addition, the MHC knockout mouse model also effectively reduces GVHD (graft versus host disease) produced by Car-T cells in mice, providing researchers with a safer experimental environment.
In addition to the MHC knockout mouse model, InnoModels also has a stable domestic platform for humanized immune system mouse models (HIS) and a platform for human tumor xenografts (PDX). Together, these sub-platforms provide strong support to the field of oncology and tumor immunopharmacodynamics CRO services, translational medicine research services and individualized medicine. They not only provide new-generation experimental animal models close to the clinic for new drug discovery companies, but also provide more comprehensive services for translational medicine researchers, tumor patients and others.
In conclusion, the InnoModels in vivo tumor experimental platform provides unprecedented convenience for researchers with its highly accurate simulation, accelerated drug development and support for multidisciplinary research. Its sub-platforms, such as the MHC knockout mouse model, the Humanized Immune System (HIS) mouse model platform, and the Human Tumor Xenotransplantation (PDX) platform, provide powerful support for the research and development of tumors and tumor immunotherapies. We have every reason to believe that with the help of InnoModels' in vivo tumor experimental platform, tumor research will achieve even more remarkable results and make greater contributions to the cause of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司